Today’s Russian clinical trial market is worth 880 million dollars
and there is every expectation that it will continue to grow. If
growth remains at the current rate of 4.65 per cent per year
to 2020, then there will be approximately 1086 new studies
compared to a total of 790 in 2013. The main contribution will
be made by big pharma sponsors and a growth in local and
bioequivalence studies stimulated by Russia’s Pharma 2020
programme. Once any myths about the Russian clinical trial
market are dispelled, the number of international clinical trials
is expected to grow at a CAGR of 11.4%, and the total clinical
trial market in Russia should hit the value of 1.6 billion dollars.
Sue Lee at World Courier focuses on Russia in this Watch Page.